Survey

CRS Diabetes Registration

You are in the right spot to register for the annual Chief Residents Summit on Intensifying Diabetes Management. Before you register, we would like your input on some initial survey questions that will help us make sure that the Summit addresses the issues and concerns that are most important to you.

Have you read either or both of the guidelines below?

[ Required ]

In patients with type 2 diabetes mellitus, the primary treatment goal is to control/reduce:

[ Required ]

Which one of the following points in managing T2DM do you find the most challenging?

[ Required ]

Please describe why this point in management is challenging for you

Please select one class of glucose-lowering medications and identify one question you have about that class

[ Required ]

Please identify the TWO greatest barriers you encounter when considering the initiation of basal insulin

[ Required ]

Which of the following patient/disease feature is correctly matched with a more stringent (lower) or less stringent (higher) A1c goal for a patient with T2D, according to the American Diabetes Association (ADA)?

[ Required ]

Which of the following drugs/classes has shown cardiovascular benefit in patients with T2D?

[ Required ]

Which of the following drug classes acts in the kidneys to lower blood glucose, and provide kidney and cardiovascular benefits in patients with T2D?

[ Required ]

I am very comfortable with the following aspect of diabetes management...

Diabetes management in general

[ Required ]

Communication

[ Required ]

Patient education/coaching

[ Required ]

Shared decision-making

[ Required ]

Promoting patient adherence & self-management

[ Required ]

Titrating doses of medication

[ Required ]

Selecting initial dosing regimens of medications

[ Required ]

Managing adverse events related to medications

[ Required ]

Initiating and modifying therapy to meet each patient's needs, interests, & capabilities

[ Required ]

Initiating treatment with a DPP-4 inhibitor

[ Required ]

Initiating treatment with a GLP-1 receptor agonist

[ Required ]

Initiating treatment with an SGLT-2 inhibitor

[ Required ]

Adding prandial insulin to basal insulin in patients with T2DM

[ Required ]

Including glucagon in a hypoglycemic treatment plan

[ Required ]

Selecting appropriate medications to reduce cardiovascular risk

[ Required ]

Balancing efficacy and safety with insulin

[ Required ]

Identifying patients who are candidates for continuous glucose monitoring

[ Required ]

Inhalable insulin

[ Required ]

When do you discuss a hypoglycemia treatment plan with your patients with diabetes? Mark all that apply

[ Required ]

If you have a patient on two diabetes drugs that are available as a combination product, how often do you switch them to the combination product?

[ Required ]

Medications in which two classes have been shown to reduce the risk of cardiovascular events compared to placebo as part of standard care?

[ Required ]

How many patients with diabetes do you see per month?

[ Required ]

What is the greatest challenge you face in managing patients with diabetes?

Now on to the actual registration...and thank you for answering all those questions!

Your Name

[ Required ]

Cell Phone - show as (XXX)XXX-XXXX

[ Invalid telephone (###)###-#### ]

Your non-Residency Program Email Address (gmail, yahoo, hotmail, etc.)

[ Invalid e-mail address ]

Residency Program

[ Required ]

Residency Program Address

[ Required ]

Name of Residency Coordinator

[ Required ]

Residency Coordinator Email

[ Invalid e-mail address ]

Name of Residency Director

[ Required ]

Residency Director Email

[ Invalid e-mail address ]

Please indicate your awareness of the following by selecting "Yes" below to show your approval.

Pictures and videos taken during the Summit may show you in attendance. I give permission for my image to be used by organizers for promotional or educational purposes

[ Required ]

Your contact up until the time of the Summit is Desma Rozovics, drozovics@iafp.com, 312-301-6232 (who will be onsite with you) or Nora Williams, nwilliams@pceconsortium.org, 704-752-0257. Don't hesitate to reach out with any questions.

AM I REGISTERED YET??? So close, but we ask one more thing!

Please email drozovics@iafp.com with anonymous patient A1c data from five (5) of your patients with T2DM and an A1c higher than 7.0. Try to pick patients whom you are likely to see regularly as we will be asking you to send another set of A1c test results from these patients in March of next year. Every year we have been able to demonstrate real world improvements using this data and we look forward to helping you make a difference with these patients. Simply express the data as "Patient One: 9.6, Patient Two: 8.1..." Email the information to drozovics@iafp.com at your earliest convenience - she will also send you a reminder.

We look forward to seeing you at the Summit!